Mesenchymal stem cells engrafted in a fibrin scaffold stimulate Schwann cell reactivity and axonal regeneration following sciatic nerve tubulization

Cartarozzi, Luciana Politti; Spejo, Aline Barroso; Ferreira, Rui Seabra; Barraviera, Benedito; Duek, Eliana A. R.; Carvalho, Juliana Lott; Góes, Alfredo M.; Oliveira, Alexandre Leite Rodrigues de

doi:10.1016/j.brainresbull.2015.01.005

Cited by 51 publications

(50 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the period of 10 weeks, the myelin fibers showed better organization of the fascicle in relation to the prior 5-week period, in which an evolutionary stage in the experimental groups was observed [36,37]. There was no evidence of inflammatory response to the sealant or foreign body reaction [38,39].…”

Section: Discussionmentioning

confidence: 82%

The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve

et al. 2016

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate the effects of low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve with two surgical techniques: end-to-end epineural suture and coaptation with heterologous fibrin sealant. Forty-two male Wistar rats were randomly divided into five groups: control group (CG) in which the buccal branch of the facial nerve was collected without injury; (2) experimental group with suture (EGS) and experimental group with fibrin (EGF): The buccal branch of the facial nerve was transected on both sides of the face. End-to-end suture was performed on the right side and fibrin sealant on the left side; (3) Experimental group with suture and laser (EGSL) and experimental group with fibrin and laser (EGFL). All animals underwent the same surgical procedures in the EGS and EGF groups, in combination with the application of LLLT (wavelength of 830 nm, 30 mW optical power output of potency, and energy density of 6 J/cm(2)). The animals of the five groups were euthanized at 5 weeks post-surgery and 10 weeks post-surgery. Axonal sprouting was observed in the distal stump of the facial nerve in all experimental groups. The observed morphology was similar to the fibers of the control group, with a predominance of myelinated fibers. In the final period of the experiment, the EGSL presented the closest results to the CG, in all variables measured, except in the axon area. Both surgical techniques analyzed were effective in the treatment of peripheral nerve injuries, where the use of fibrin sealant allowed the manipulation of the nerve stumps without trauma. LLLT exhibited satisfactory results on facial nerve regeneration, being therefore a useful technique to stimulate axonal regeneration process.

show abstract

Section: Discussionmentioning

confidence: 82%

The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Standardized for over 20 years by a consortium of Brazilian researchers, several preclinical studies and clinical trials have already been completed. Thus, preclinical trials applying the product in the peripheral nervous and musculoskeletal systems [46–56] and as a scaffold for stem cells have been studied extensively [57–60]. Trials in plastic surgery skin repair [61], periodontal surgery [62–64] and in chronic venous ulcers have also been performed [41, 65].…”

Section: Discussionmentioning

confidence: 99%

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Ferreira

Barros

Abbade

et al. 2017

J Venom Anim Toxins Incl Trop Dis

Self Cite

View full text Add to dashboard Cite

Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.Electronic supplementary materialThe online version of this article (doi:10.1186/s40409-017-0109-8) contains supplementary material, which is available to authorized users.

show abstract

“…Multiple studies in animal models have demonstrated the ability of MSCs to facilitate peripheral nerve regeneration through differentiation into and interaction with SC [175][176][177][178][179]. Local administration of adipose-derived MSCs in a mouse model of a crush nerve injury demonstrated improved recovery of motor and sensory function [180], and recovery of motor function was also improved by MSC treatment in a rat model of nerve transection [176]. Both groups suggest brainderived neurotropic factor and components of the myelin sheath produced by MSCs as the primary mechanisms supporting neuroregeneration [176,180].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Exploring cell-based tolerance strategies for hand and face transplantation

Fryer

Grahammer

Khalifian

et al. 2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Broader clinical application of reconstructive hand and face transplantation is hindered by the need for lifelong immunosuppression for allograft maintenance. In this review, we summarize various cell-based approaches to tolerance induction currently under investigation in both clinical and pre-clinical models to alleviate the need for chronic immunosuppression. These include strategies to induce mixed hematopoietic chimerism, therapy with T and B regulatory cells, regulatory macrophages, tolerogenic dendritic cells, and mesenchymal stem cells. The vascularized, intragraft bone components inherent to reconstructive transplants serve as a continuous source of donor-derived hematopoietic cells, and make hand and face transplants uniquely well suited for cell-based approaches to tolerance that may ultimately tilt the risk-benefit balance for these life-changing, but not life-saving, procedures.

show abstract

Mesenchymal stem cells engrafted in a fibrin scaffold stimulate Schwann cell reactivity and axonal regeneration following sciatic nerve tubulization

Cited by 51 publications

References 47 publications

The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve

The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Exploring cell-based tolerance strategies for hand and face transplantation

Contact Info

Product

Resources

About